ACTH(4-10) is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
They Hunger features little original Half-Life content apart from the revolver, some sound clips, a few types of ammunition the player can pick up, and a few other minor details, although many weapons and NPCs are simply re-skins of the content in Half-Life. For example, the civilians are re-skins of a scientist found in Half-Life. It also includes the flamethrower and sniper rifle from Team Fortress Classic, though it features a different view when scoped. In addition to these modifications, it changes the sounds of certain characters. For example, one friendly NPC features the same sound clips as Barney Calhoun from Half-Life but has been edited to affect a deeper voice. Zombies and headcrabs have also been given voices, which add to the horror aspect of the game. Two deathmatch maps were released separately ahead of the first episode's release. They Hunger 2 and 3 include a multiplayer deathmatch mode. Barking Dog Studios and Gooseman were reported to be involved in the production of They Hunger 2.
Miglitol is an oral alpha-glucosidase inhibitor used in the treatment of type 2 diabetes. It works by reversibly inhibiting alpha-glucosidase enzymes in the small intestine, which delays the digestion of complex carbohydrates and subsequently reduces postprandial glucose levels. Approved for clinical use since 1998, miglitol has demonstrated efficacy in improving glycemic control, reducing HbA1c levels, and decreasing both fasting and postprandial plasma glucose concentrations in long-term clinical trials. Additionally, recent studies have suggested that miglitol may have potential as an anti-obesity agent, showing promise in reducing body weight and body mass index in obese or diabetic patients. While generally well-tolerated, the most common side effects associated with miglitol are gastrointestinal disturbances, which are typically mild to moderate and tend to decrease over time. It must be taken at the start of main meals to have maximal effect In contrast to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.
Christianity is the largest religion in Ghana, with 71.3% of the population being members of various Christian denominations as of the 2021 census. Islam is practiced by 16.8% of the total population. According to a 2012 report by Pew Research, 60.71% of Muslims are followers of Sunni Islam, while around 9.52% identify with Shia Islam, while the remainder 29.76% are non-denominational Muslims. There is "no significant link between ethnicity and religion in Ghana". Approximately 16% belong to the Ahmadiyya religion. Rest 8.7% are others. Ghana has around 150,000 Jehovah's Witnesses. The Grand Orange Lodge of Ghana is a Protestant fraternal organization within the Orange Order. The one governed by the Grand Lodge is The Loyal Leopold Lodge No. 907. It was founded in 1894 by a British colonial official, Dr. A. D. MacDonald. The lodge initially served as a social club for European administrators, military officers, and merchants. Over time, it began to admit local African members, which was a departure from the lodges in Ireland and Britain that were overwhelmingly white and Protestant. Its members participate in events and parades, including The Twelfth. They also are involved in community and charitable work.
== Examples == Morphine is the prototype of opioid analgesics Propranolol is the prototype of the beta blockers Chlorpromazine is the prototypical phenothiazine antipsychotic Imipramine is the prototypical tricyclic antidepressant, and itself a derivative of chlorpromazine Diazepam is the prototype of the benzodiazepine Diphenhydramine (Benadryl) is the prototype ethanolamine antihistamine Nifedipine is the prototype dihydropyridine calcium channel blocker Chloroquine is the prototypical antimalarial agent Acyclovir is the prototype antiviral agent that is activated by viral thymidine kinase Aspirin is the prototype NSAID Dextroamphetamine is the prototype Stimulant Omeprazole is the prototype Proton-pump inhibitor
PEPAP (phenethylphenylacetoxypiperidine) is an opioid analgesic that is an analog of desmethylprodine. It is related to the drug MPPP, with an N-phenethyl group in place of the N-methyl substitution and an acetate ester rather than propionate. PEPAP is approximately 6–7 times more potent than morphine in laboratory rats. PEPAP presumably has similar effects to other opioids, producing analgesia, sedation and euphoria. Side effects can include itching, nausea and potentially serious respiratory depression which can be life-threatening. PEPAP has been found to be a potent CYP2D6 inhibitor, which makes it likely to cause adverse interactions with some other drugs, although the inhibitory potency of PEPAP is less than that of MPPP. Both cocaine and methadone are also CYP2D6 inhibitors and could, in theory, potentiate the effect. It is unlikely that the tetrahydropyridine byproducts that may be formed during the synthesis of PEPAP are neurotoxic in the same way as the MPPP byproduct MPTP. It appears that the N-methyl group of MPTP is required for neurotoxic activity. In animal experiments, only MPTP analogues that preserved the N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine structure were active as dopaminergic neurotoxins. Most structural changes, including replacing the N-methyl group with other substituents, abolished neurotoxicity. There is evidence that the clandestine manufacturers who produced MPPP in the 1970s, including the tainted batch, went on to produce PEPAP in an attempt to avoid using watched precursors or drug intermediates that were illegal.
Sources: en.wikipedia.org
== External links == Cabinet nod to cold chain centre : News Centre to reduce gaps in infrastructure :Agriculture Minister Cold chain draws (Indian) government attention- Industry Magazine What is NCCD :General knowledge essay Archived 2013-03-30 at the Wayback Machine India: Huge foreign investment opportunities in cold chain :Fresh Plaza news FDI in multi-brand retail is Heating up the Cold :FDI discussion Indian Cold chain industry to reach USD 11 billion by 2017 :Report India earned Rs 14000 crore (USD 2690 million) from export of horticultural produce 2012 :Report Archived 2019-02-22 at the Wayback Machine Effective Cold Chains Help Productivity :Report Faster movement of refrigerated vans on anvil :News System Standards and Guidelines for cold-chain infrastructure :Document Archived 2019-07-28 at the Wayback Machine Without Cooling, Most Modern Society Would Crumble :Forbes article How Cold-Chain Can Minimize Food Loss :Huffington Post Kinnow Cold Chain Study :Document Paradigm Shifts In India’s Agricultural Policy :Huffington Post Doubling farmers’ income by reducing food loss :News University of Birmingham appoints cold chain expert Kohli as professor :News" India to consider communal cooling hub potential :Report Deliberating Ways on Boosting EU -India Trade in Agri-products :Report CEO NCCD to demit office :News
=== Framing theory === Framing theory is a mass communications theory that explains how information can be structured and disseminated to promote a specific view on a particular issue. In the context of mental illness portrayals, the media's framing of information about health and mental illnesses can affect an audience's attitudes and beliefs toward those illnesses. As framing is most commonly associated with negative effects, it also has the power to redefine and destigmatize mental illnesses.
ELGA LabWater is the laboratory water brand name of Veolia Water Solutions & Technologies. ELGA manufactures, supplies and services water purification systems for use in general, R&D, healthcare and clinical laboratories. Its offices and distributors are located in more than 60 countries.
The ECR ion source makes use of the electron cyclotron resonance to ionize a plasma. Microwaves are injected into a volume at the frequency corresponding to the electron cyclotron resonance, defined by the magnetic field applied to a region inside the volume. The volume contains a low pressure gas.
Sources: en.wikipedia.org
=== Acquisition and merging of Novartis' vaccine business === In October 2014, Novartis announced its intention to sell its influenza vaccine business, including its development pipeline, to CSL for $275 million. CSL merged it into its BioCSL operation. In November 2015, BioCSL rebranded the combined business with Novartis Influenza Vaccines as Seqirus [Sek-eer-us], creating the world's second-largest influenza vaccine company. In August 2017, the business announced it would acquire Calimmune and its stem cell therapy platform. Completed in 2018, Seqirus's plant in Holly Spring, NC was funded with $59 million from the U.S. government. in June 2020, CSL announced it would exercise its right to acquire Vitaeris. In December 2021, the business announced it would acquire Swiss drugmaker, Vifor Pharma AG, for $11.7 billion. In August 2022, CSL rebranded all of its divisions to start with the CSL name. Therefore, the divisions became CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor.
The most common method for chiral resolution involves conversion of the racemic mixture to a pair of diastereomeric derivatives by reacting them with chiral derivatizing agents, also known as chiral resolving agents. The derivatives which are then separated by conventional crystallization, and converted back to the enantiomers by removal of the resolving agent. The process can be laborious and depends on the divergent solubilities of the diastereomers, which is difficult to predict. Often the less soluble diastereomer is targeted and the other is discarded or racemized for reuse. It is common to test several resolving agents. Typical derivatization involves salt formation between an amine and a carboxylic acid. Simple deprotonation then yields back the pure enantiomer. Examples of chiral derivatizing agents are tartaric acid and the amine brucine. The method was introduced (again) by Louis Pasteur in 1853 by resolving racemic tartaric acid with optically active (+)-cinchotoxine. In some cases, only 0.5 equivalents of a chiral acid or base are reqiured.
== Pharmacology == EPO is highly glycosylated (40% of total molecular weight), with half-life in blood around 5 h. EPO's half-life may vary between endogenous and recombinant versions. Additional glycosylation or other alterations of EPO via recombinant technology have led to the increase of EPO's stability in blood (thus requiring less frequent injections).
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.